Literature DB >> 9286948

Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction?: Power spectral analysis in patients with non-insulin-dependent diabetes and nondiabetic subjects.

J P Töyry1, L K Niskanen, M J Mäntysaari, E A Länsimies, S M Haffner, H J Miettinen, M I Uusitupa.   

Abstract

BACKGROUND: Immunoreactive insulin has been shown to predict the development of parasympathetic autonomic neuropathy. It is possible that constituents of immunoreactive insulin could explain this association. In this cross-sectional study, the relationship of specific insulin, C-peptide, and proinsulin with autonomic nervous dysfunction was evaluated in 57 NIDDM patients and 108 control subjects. METHODS AND
RESULTS: The frequency-domain analysis of heart rate variability was determined by using spectral analysis from stationary regions of registrations while the subjects breathed spontaneously in a supine position. Total power was divided into three frequency bands: low (0 to 0.07 Hz), medium (MFP, 0.07 to 0.15 Hz), and high (HFP, 0.15 Hz to 0.50 multiplied by the frequency equal to the mean RR interval). In NIDDM patients, total power, the three frequency bands (P<.001 for each), and the MFP/HFP ratio (P=.016), which expresses sympathovagal balance, were reduced compared with control subjects. Fasting proinsulin (r(s)=-.324, P=.014 for diabetics and r(s)=-.286, P=.003 for control subjects), C-peptide (r(s)=-.492, P<.001 for diabetics and r(s)=-.304, P=.001 for control subjects), and total immunoreactive insulin (r(s)=-.291, P=.028 for diabetics and r(s)=-.228, P=.017 for control subjects) were inversely related to MFP/HFP. For proinsulin and C-peptide the results did not change after controlling for the effects of age, body mass index, and fasting glucose.
CONCLUSIONS: Both proinsulin and C-peptide levels were significantly associated with the sympathovagal balance of autonomic nervous function in NIDDM patients and control subjects, but this study cannot determine whether these compounds are directly involved in autonomic nervous dysfunction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286948     DOI: 10.1161/01.cir.96.4.1185

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Disparity of autonomic control in type 2 diabetes mellitus.

Authors:  R J Huggett; E M Scott; S G Gilbey; J Bannister; A F Mackintosh; D A S G Mary
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

2.  Autonomic dysfunction is related to impaired pancreatic beta cell function in patients with coronary artery disease.

Authors:  J W Sayer; B Marchant; S V Gelding; J A Cooper; A D Timmis
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

3.  Relationship between C peptide and chronic complications in type-2 diabetes mellitus.

Authors:  Ramazan Sari; Mustafa Kemal Balci
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

4.  Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.

Authors:  P Valensi; S Chiheb; M Fysekidis
Journal:  Diabetologia       Date:  2013-04-13       Impact factor: 10.122

5.  Links between metabolic syndrome and cardiovascular autonomic dysfunction.

Authors:  G Garruti; F Giampetruzzi; M G Vita; F Pellegrini; P Lagioia; G Stefanelli; A Bellomo-Damato; F Giorgino
Journal:  Exp Diabetes Res       Date:  2012-03-15

6.  Continuous multi-parameter heart rate variability analysis heralds onset of sepsis in adults.

Authors:  Saif Ahmad; Tim Ramsay; Lothar Huebsch; Sarah Flanagan; Sheryl McDiarmid; Izmail Batkin; Lauralyn McIntyre; Sudhir R Sundaresan; Donna E Maziak; Farid M Shamji; Paul Hebert; Dean Fergusson; Alan Tinmouth; Andrew J E Seely
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

7.  Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients.

Authors:  Hye-Jin Yoon; Youn-Zoo Cho; Ji-Young Kim; Byung-Joon Kim; Keun-Young Park; Gwan-Pyo Koh; Dae-Ho Lee; Dong-Mee Lim
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.